Cardiovascular risk profiles: A cross‐sectional study evaluating the generalizability of the glucagon‐like peptide‐1 receptor agonist cardiovascular outcome trials REWIND , LEADER and SUSTAIN ‐6 to the real‐world type 2 diabetes population in the United Kingdom
Diabetes Obesity and Metabolism2021Vol. 24(2), pp. 289–295
Citations Over TimeTop 18% of 2021 papers
Joanne Webb, Julie Mount, Lill‐Brith von Arx, Jonathan Rachman, Dionysis Spanopoulos, Robert Wood, Theo Tritton, Olivia Massey, Iskandar Idris
Abstract
REWIND captured a trial population more representative of the real-world T2D population in the United Kingdom than LEADER or SUSTAIN-6 with regard to both CV and combined CV/core eligibility criteria.
Related Papers
- → Generalizing Generalizability in Information Systems Research(2003)1,544 cited
- → Applying Generalizability Theory using EduG(2011)108 cited
- → Reliability of observers' subjective impressions of families: A generalizability theory approach(2012)20 cited
- → Using Generalizability Theory for the Estimation of Reliability of a Patient Classification System(1994)1 cited